Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient ...
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of ...
CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics ...
Detailed price information for Camp4 Therapeutics Corp (CAMP-Q) from The Globe and Mail including charting and trades.
Sherry Gao, Tyler Daniel (pictured) and their coauthors developed a new tool that can simultaneously and independently edit multiple genes and regulate their expression. Influential inventions often ...
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results